Trastuzumab deruxtecan recommended in NICE draft guidance for use in the CDF for breast cancer after two or more anti-HER2 therapies

More data from trials and NHS practice are needed to help address the uncertainty about clinical effectiveness.

Join OnMedica and benefit from:

  • Bitesize CPD and easy to digest content, free for UK-based GPs and specialist doctors
  • High-quality, evidence-based content developed by expert editors and clinicians
  • Articles, quizzes, videos, visual summaries and more
  • Regulatory alerts and round-up of medical journals
  • New content added daily, so you know you’re always up to date

Existing members Sign in